Zions Bancorporation N.A. Has $4.16 Million Stake in Integer Holdings Co. (NYSE:ITGR)

Zions Bancorporation N.A. raised its position in Integer Holdings Co. (NYSE:ITGR) by 19.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,413 shares of the medical equipment provider’s stock after acquiring an additional 5,095 shares during the quarter. Zions Bancorporation N.A.’s holdings in Integer were worth $4,163,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Mather Group LLC. increased its holdings in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 143 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in Integer during the fourth quarter worth approximately $27,000. R Squared Ltd acquired a new stake in Integer during the 4th quarter worth approximately $44,000. Versant Capital Management Inc boosted its position in shares of Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. boosted its holdings in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 152 shares during the period. Institutional investors own 99.29% of the company’s stock.

Analysts Set New Price Targets

ITGR has been the subject of a number of recent analyst reports. Citigroup upped their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Truist Financial increased their price target on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Benchmark upped their target price on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price target on shares of Integer in a research note on Tuesday, December 3rd. Finally, KeyCorp raised their price objective on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Integer currently has an average rating of “Moderate Buy” and a consensus target price of $149.00.

Integer Trading Up 1.7 %

NYSE ITGR opened at $117.13 on Tuesday. Integer Holdings Co. has a twelve month low of $107.11 and a twelve month high of $146.36. The business’s fifty day moving average is $132.23 and its 200 day moving average is $132.29. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 34.86, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The firm had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, sell-side analysts expect that Integer Holdings Co. will post 6.01 EPS for the current fiscal year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.